Incyte Secures $246M Non-Cash Benefit from CMS Settlement on Opzelura
INCY sits 49% above its 52-week low of $66.74 on elevated volume (2.5× avg).
Summary
Incyte has reached a settlement with the Centers for Medicare & Medicaid Services (CMS) regarding its drug Opzelura, resulting in a $246 million non-cash benefit. This agreement clarifies that Opzelura will not be treated as a line extension of Jakafi under Medicaid rebate rules, leading to the reversal of prior accruals. The company expects improved gross-to-net for Opzelura going forward, which is a positive for the product's future profitability. Financial guidance will be updated at the next scheduled earnings release.
At the time of this announcement, INCY was trading at $99.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.6B. The 52-week trading range was $66.74 to $112.29. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.